| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Endocrinology (H.E.T., J.A.H.W.), Churchill Hospital, Oxford OX3 7LJ, United Kingdom; Molecular Angiogenesis Group (A.L.H.), Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, OX3 9DU Oxford, United Kingdom; and Davis Research Institute (S.M.), Cedars Sinai Hospital, Los Angeles, California 90048
Correspondence: Address all correspondence and requests for reprints to: Dr. Helen E. Turner, Department of Endocrinology, Churchill Hospital, Old Road, Oxford OX3 7LJ, United Kingdom. E-mail: jenny.Thomson{at}orh.nhs.uk
Angiogenesis is the process of new blood vessel development from preexisting vasculature. Although vascular endothelium is usually quiescent in the adult, active angiogenesis has been shown to be an important process for new vessel formation, tumor growth, progression, and spread. The angiogenic phenotype depends on the balance of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and inhibitors, as well as interactions with the extracellular matrix, allowing for endothelial migration. Endocrine glands are typically vascular organs, and their blood supply is essential for normal function and tight control of hormone feedback loops. In addition to metabolic factors such as hypoxia, the process of angiogenesis is also regulated by hormonal changes such as increased estrogen, IGF-I, and TSH levels.
By measuring microvascular density, differences in angiogenesis have been related to differences in tumor behavior, and similar techniques have been applied to both benign and malignant endocrine tumors with the aim of identification of tumors that subsequently behave in an aggressive fashion.
In contrast to other tumor types, pituitary tumors are less vascular than normal pituitary tissue, although the mechanism for this observation is not known. A relationship between angiogenesis and tumor size, tumor invasiveness, and aggressiveness has been shown in some pituitary tumor types, but not in others. There are few reports on the role of microvascular density or angiogenic factors in adrenal tumors. The mechanism of the vascular tumors, which include adrenomedullary tumors, found in patients with Von Hippel Lindau disease has been well characterized, and clinical trials of antiangiogenic therapy are currently being performed in patients with Von Hippel Lindau disease. Thyroid tumors are more vascular than normal thyroid tissue, and there is a clear correlation between increased VEGF expression and more aggressive thyroid tumor behavior and metastasis. Although parathyroid tissue induces angiogenesis when autotransplanted and PTH regulates both VEGF and MMP expression, there are few studies of angiogenesis and angiogenic factors in parathyroid tumors.
An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment.
This article has been cited by other articles:
 |
|
 |
|
  N. Figueroa-Vega, P. Sanz-Cameno, R. Moreno-Otero, F. Sanchez-Madrid, R. Gonzalez-Amaro, and M. Marazuela Serum Levels of Angiogenic Molecules in Autoimmune Thyroid Diseases and Their Correlation with Laboratory and Clinical Features J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1145 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Kloos, M. D. Ringel, M. V. Knopp, N. C. Hall, M. King, R. Stevens, J. Liang, P. E. Wakely Jr, V. V. Vasko, M. Saji, et al. Phase II Trial of Sorafenib in Metastatic Thyroid Cancer J. Clin. Oncol., April 1, 2009; 27(10): 1675 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Raina, S. Rajamanickam, R. P. Singh, G. Deep, M. Chittezhath, and R. Agarwal Stage-Specific Inhibitory Effects and Associated Mechanisms of Silibinin on Tumor Progression and Metastasis in Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., August 15, 2008; 68(16): 6822 - 6830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Balthasar, N. Bergelin, C. Lof, M. Vainio, S. Andersson, and K. Tornquist Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells Endocr. Relat. Cancer, June 1, 2008; 15(2): 521 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Vaupel Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis Oncologist, May 1, 2008; 13(suppl_3): 21 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Korsisaari, J. Ross, X. Wu, M. Kowanetz, N. Pal, L. Hall, J. Eastham-Anderson, W. F. Forrest, N. Van Bruggen, F. V. Peale, et al. Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1 Clin. Cancer Res., January 1, 2008; 14(1): 249 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-J. Hsiao, M.-Y. Lu, F.-Y. Chiang, S.-J. Shin, Y.-D. Tai, and S.-H. H. Juo Vascular endothelial growth factor gene polymorphisms in thyroid cancer J. Endocrinol., November 1, 2007; 195(2): 265 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Klubo-Gwiezdzinska, R. Junik, E. Kopczynska, O. Juraniec, and H. Kardymowicz The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter Eur. J. Endocrinol., October 1, 2007; 157(4): 521 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Erbil, Y. Ozluk, M. Giris, A. Salmaslioglu, H. Issever, U. Barbaros, Y. Kapran, S. Ozarmagan, and S. Tezelman Effect of Lugol Solution on Thyroid Gland Blood Flow and Microvessel Density in the Patients with Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2182 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Boikos and C. A. Stratakis Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis Hum. Mol. Genet., April 15, 2007; 16(R1): R80 - R87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Naumov, R. S. Watnick, N. Almog, L. A. Akslen, and J. Folkman Response: Re: A Model of Human Tumor Dormancy: An Angiogenic Escape From the Nonangiogenic Phenotype J Natl Cancer Inst, February 21, 2007; 99(4): 331 - 332. [Full Text] [PDF]
|
|
|
|
|
|
A. J Sarkar, K. Chaturvedi, C. P. Chen, and D. K Sarkar Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors J. Endocrinol., February 1, 2007; 192(2): 395 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Paisley, C. J. O'Callaghan, K. C. Lewandowski, C. Parkinson, M. E. Roberts, W. M. Drake, J. P. Monson, P. J. Trainer, and H. S. Randeva Reductions of Circulating Matrix Metalloproteinase 2 and Vascular Endothelial Growth Factor Levels after Treatment with Pegvisomant in Subjects with Acromegaly J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4635 - 4640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Onofri, M. Theodoropoulou, M. Losa, E. Uhl, M. Lange, E. Arzt, G. K Stalla, and U. Renner Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J. Endocrinol., October 1, 2006; 191(1): 249 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ohnemus, M. Uenalan, J. Inzunza, J.-A. Gustafsson, and R. Paus The Hair Follicle as an Estrogen Target and Source Endocr. Rev., October 1, 2006; 27(6): 677 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, et al. An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4070 - 4076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pasquali, V. Rossi, S. Staibano, G. De Rosa, P. Chieffi, D. Prezioso, V. Mirone, M. Mascolo, D. Tramontano, A. Bellastella, et al. The Endocrine-Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF)/Prokineticin 1 and 2 and Receptor Expression in Human Prostate: Up-Regulation of EG-VEGF/Prokineticin 1 with Malignancy Endocrinology, September 1, 2006; 147(9): 4245 - 4251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C Lazaris, S. Tseleni-Balafouta, T. Papathomas, T. Brousalis, G. Thomopoulou, G. Agrogiannis, and E. S Patsouris Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions. Eur. J. Endocrinol., June 1, 2006; 154(6): 827 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G M Besser, P Burman, and A F Daly Predictors and rates of treatment-resistant tumor growth in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Adhami, I. A. Siddiqui, N. Ahmad, S. Gupta, and H. Mukhtar Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I-Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer Cancer Res., December 1, 2004; 64(23): 8715 - 8722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. B. Davis, S. A. Mousa, L. O'Connor, S. Mohamed, H.-Y. Lin, H. J. Cao, and P. J. Davis Proangiogenic Action of Thyroid Hormone Is Fibroblast Growth Factor-Dependent and Is Initiated at the Cell Surface Circ. Res., June 11, 2004; 94(11): 1500 - 1506. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
